| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | May 12, 2026 4:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
8-K - bioAffinity Technologies, Inc. (0001712762) (Filer)
S-8 - bioAffinity Technologies, Inc. (0001712762) (Filer)
Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in their practices CyPath® Lung has demonstrated the ability to aid in the detection of early-stage lung cancer and support surveillance of cancer survivors for recurrence bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today announced the Society for Advanced Bronchoscopy (SAB) will host a webinar on CyPath® Lung's expanding role in pulmonary, oncology and surgical practices for the detection and management of early-stage lung cancer. The live
Strong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung's flow cytometry-driven diagnostic approach in international markets bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the Company's commercially available test for early-stage lung cancer, today announced it has received notification of allowance from the Mexican Institute of Industrial Property for a patent application related to methods of predicting the likelihood of lung cancer using flow cytometry. Upon issuance, the Mexican patent application will protect the use of defined antibod
CyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026 trend of accelerating adoption and clinical use Noninvasive test has potential to transform lung cancer risk assessment and nodule management bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that unit sales for its CyPath® Lung diagnostic test achieved a record high in a single month and increased nearly 300% in April 2026 compared to the same period in 2025, based on preliminary unaudited data. The strong CyPath® Lung unit sales growt
3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
3 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
4 - bioAffinity Technologies, Inc. (0001712762) (Issuer)
Advisory Board provides independent guidance on strategic priorities, including growing adoption of the Company's noninvasive CyPath® Lung diagnostic test bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced new appointments to its Medical and Scientific Advisory Board, welcoming David Ost, MD, MPH, University of Texas MD Anderson Cancer Center, Daniel Sterman, MD, New York University Langone Medical Center, and J. Scott Ferguson, MD, University of Wisconsin School of Medicine and Public Health, to its panel of recognized leaders in the field. The appointments reflect a planned expans
Financial and Clinical Leaders Provide Significant Expertise for the Company's Commercial Growth bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company advancing noninvasive diagnostics for the early detection of lung cancer and other diseases, today announced the appointment of Roberto Rios, CPA, and John J. Oppenheimer, M.D., to its Board of Directors. "Mr. Rios' business and financial expertise combined with Dr. Oppenheimer's clinical leadership will be invaluable as we increase sales of CyPath® Lung, develop companion diagnostics for asthma and COPD, and strengthen our financial position," said Maria Zannes, President and CEO of bioAffinity Technologies. Mr.
bioAffinity Technologies, Inc. (NASDAQ:BIAF, BIAFW)), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other diseases of the lung, today announced that its President and CEO, Maria Zannes, has been selected to serve on the American Lung Association in Texas' Leadership Board, a distinguished group of healthcare professionals and advocates committed to advancing lung health. As a member of the Texas Leadership Board, Ms. Zannes will play an important role in supporting the Lung Association's mission to improve lives by preventing lung disease and promoting lung health through research, education and advocacy. Board
ORLANDO, FL / ACCESSWIRE / January 10, 2025 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (NASDAQ:ENLV) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, January 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ENLV: https://www.redchip.com/assets/access/enlv_accessBIAF: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Oren Hershkovitz, CEO of Enlivex Therapeutics, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a c
ORLANDO, FL / ACCESSWIRE / July 12, 2024 / RedChip Companies will air interviews with Biotricity, Inc. (NASDAQ:BTCY) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 13, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Biotricity: https://www.redchip.com/assets/access/btcy_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Dr. Waqaas Al-Siddiq, Founder and CEO of Biotricity, will share insight into the company's innovative portfolio of car
ORLANDO, FL / ACCESSWIRE / July 5, 2024 / RedChip Companies will air interviews with BioVie, Inc. (NASDAQ:BIVI) and bioAffinity Technologies, Inc. (NASDAQ:BIAF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 6, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:BioVie: https://www.redchip.com/assets/access/bivi_accessbioAffinity Technologies: https://www.redchip.com/assets/access/biaf_accessIn an exclusive interview, Cuong Do, President and CEO of BioVie, who will share insight into the Company's pipeline of late-stage clinical programs target
SC 13G - bioAffinity Technologies, Inc. (0001712762) (Subject)